10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing whether JAK inhibitors offer value for money for the treatment of rheumatoid arthritis in the USA, at the same time as publishing recommendations on how to stop the current 'upward trajectory' of drug prices. 10 January 2020
The US Food and Drug Administration has approved Ayvakit (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. 10 January 2020
US hematopoietic cell transplant therapies focussed biotech Jasper Therapeutics has expanded its Series A financing with an additional investment of $14.1 million led by Roche Venture Fund and with participation from other investors, bringing the total company financing to more than $50 million to date. 10 January 2020
Further replenishing its R&D pipeline in the face of falling sales for some its blockbuster anti-viral drugs and an aging HIV portfolio, Gilead Sciences has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074. 9 January 2020
German family-owned pharma major says it has entered into a worldwide exclusive license deal to acquire Singapore-based biotech Enleofen Bio’s pre-clinical interleukin-11 (IL-11) platform to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. 9 January 2020
Germany’s BioMed X has unveiled a new joint research group, in collaboration with Merck KGaA, the sixth such collaborative project between the two companies. 9 January 2020
Shares in French peanut allergy specialist DBV Technologies were boosted 20% in pre-market trading on Thursday, after the firm announced positive topline results from the Phase III PEPITES trial. 9 January 2020
The US regulator has added another approval to the list for Merck & Co’s Keytruda (pembrolizumab), as monotherapy for certain people with non-muscle invasive bladder cancer (NMIBC). 9 January 2020
Altavant Sciences has entered into a definitive agreement to acquire USA-based Onspira Therapeutics, a private drug development company similarly focused on therapeutics for rare pulmonary diseases. 9 January 2020
US biopharma Immunic has opted to exercise an exclusive global option to license a group of compounds, designated as IMU-856, from Daiichi Sankyo. 8 January 2020
Japanese drugmaker Kyowa Kirin today said that it has submitted a supplemental application for Lumicef (brodalumab) for the treatment of axial spondyloarthritis (axSpA) in Japan. 8 January 2020
UK-based Avacta Group and Korean pharma Daewoong Pharmaceutical are to form a joint venture (JV) aimed at developing cell and gene therapies incorporating the Cambridge-based company’s Affimer proteins. 8 January 2020
A new collaboration between Aragen Bioscience and Serum Institute of India will see the development of multiple stable cell lines in support of the latter’s HIV program. 8 January 2020
Spain’s largest drugmaker could be about to get bigger with the news that Almirall has entered into an option agreement to buy Bioniz Therapeutics to further expand its pipeline in dermatology. 8 January 2020